Needham analyst Michael Matson maintained a Buy rating on LivaNova (LIVN – Research Report) today and set a price target of $64.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Michael Matson has given his Buy rating due to a combination of factors, despite the recent challenges faced by LivaNova. The company experienced a temporary setback in its US Epilepsy business due to a voluntary field safety notice, which led to some procedure deferrals and a $2 million impact. However, LivaNova has already received FDA approval for a redesigned version of the affected product and plans to launch it in the latter half of 2025.
Matson’s confidence in LivaNova’s future performance is reflected in the unchanged annual revenue and EPS estimates for 2025 and 2026. This suggests that the temporary issues are not expected to have a long-term impact on the company’s financial health. The proactive steps taken by LivaNova to address the design issue and the anticipated product launch are seen as positive indicators for the company’s growth prospects.
Matson covers the Healthcare sector, focusing on stocks such as LivaNova, TransMedics Group, and Atricure. According to TipRanks, Matson has an average return of -6.9% and a 39.08% success rate on recommended stocks.
In another report released on May 8, Robert W. Baird also maintained a Buy rating on the stock with a $61.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue